Designation of Canakinumab (Ilaris) as an Orphan Drug - Novartis Pharmaceuticals Australia Pty Limited

Overview

The designation of Canakinumab (ILARIS) as an orphan drug was announced on 11 April 2013 by Dr Anthony Gill, acting as the Delegate of the Secretary for the purposes of the Therapeutic Goods Regulations 1990. This action was taken to address the need for treatments specifically targeting rare diseases that have a significant impact on patients' quality of life. By designating Canakinumab as an orphan drug, the legislation aims to encourage the development and availability of effective treatments for the condition, in this case, active Systemic Juvenile Idiopathic Arthritis (sJIA) in patients aged 2 years and older. This policy objective aligns with the overarching aim of the Therapeutic Goods Regulations 1990, which seeks to ensure that therapeutic goods are safe, of high quality, and meet the needs of Australians, particularly those with rare medical conditions.

Scope and Application

This legislation pertains to the designation of Canakinumab (ILARIS) as an orphan drug for the treatment of active Systemic Juvenile Idiopathic Arthritis (sJIA) in patients aged 2 years and older. The act is executed under the Therapeutic Goods Regulations 1990, specifically under subregulation 16J(2), by Dr Anthony Gill, who is designated as the Delegate of the Secretary. The orphan drug designation applies to Canakinumab (ILARIS) in its powder for injection form and is intended for patients with the specified medical condition. The sponsor of the drug, responsible for its development and distribution within the scope of this legislation, is Novartis Pharmaceuticals Australia Pty Limited. The designation applies nationally within Australia, but the specific therapeutic use of the drug is restricted to the treatment of sJIA in the specified patient demographic. There are no exclusions, exemptions, or thresholds mentioned in this particular legislation, but the application and regulation of the drug can be further defined and potentially extended or restricted through subordinate instruments under the broader regulatory framework of the Therapeutic Goods Regulations 1990.

Key Provisions

The primary operative sections of this legislation (C2013G00653) designate Canakinumab (ILARIS) as an orphan drug for the treatment of active Systemic Juvenile Idiopathic Arthritis (sJIA) in patients aged two years and older. This designation, effective from 11 April 2013, is detailed in section 1, which references the Therapeutic Goods Regulations 1990 (the Regulations). The specific section in question is 16J, with the designation being made under subregulation 16J(2). The drug's form for this indication is Powder for Injection, and the sponsor responsible for this therapeutic good is Novartis Pharmaceuticals Australia Pty Limited. This legislative action recognises the rarity and specific needs associated with the treatment of sJIA in younger patients. The obligations and requirements imposed by this legislation primarily concern the sponsor, Novartis Pharmaceuticals Australia Pty Limited. As the sponsor, they are responsible for ensuring that Canakinumab (ILARIS) meets the necessary standards for safety, efficacy, and quality for the designated use. This includes adhering to all relevant provisions of the Therapeutic Goods Act 1989 and the Regulations. The designation as an orphan drug also entails certain incentives, such as streamlined regulatory processes and potential market exclusivity, which are intended to encourage the development of treatments for rare diseases. The sponsor must also ensure that they provide accurate and complete information to the Therapeutic Goods Administration (TGA) regarding the drug’s use, benefits, and any associated risks. Under this legislation, breaches of the Therapeutic Goods Act 1989 or the Regulations can result in significant penalties and consequences. The specific offences, penalties, or civil and criminal consequences for non-compliance can vary widely depending on the nature and severity of the breach. For instance, offences may include the unauthorised manufacture, supply, or advertising of therapeutic goods, which can attract substantial fines. For individuals, the maximum penalty for serious offences can be up to five years' imprisonment or fines up to $330,000, or both, as outlined in section 32 of the Act. For corporations, the maximum penalties can be even higher, reflecting the seriousness of the potential public health risks involved. In addition to criminal penalties, civil actions may also be pursued, which can include court-ordered compensation for damages or other remedies. The precise consequences will depend on the specific circumstances of the breach and the discretion of the court.